Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 680-692

  Smerage, Jeffrey B ^a   Budd, G Thomas ^b   Doyle, Gerald V ^c   Brown, Marty ^a   Paoletti, Costanza ^a   Muniz, Maria ^a   Miller, M Craig ^c   Repollet, Madeline I ^c   Chianese, David A ^c   Connelly, Mark C ^c   Terstappen, Leon W W M ^d   Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c Veridex LLC   (United States)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Apoptosis; Bcl 2; Breast cancer; Circulating tumor Cells

Indexed keywords

PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BREAST METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CELL ISOLATION; CIRCULATING TUMOR CELL; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SYSTEMIC THERAPY;

EID: 84878112695     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.013     Document Type: Article

References (55)

1. Albain K.S., Barlow W.E., Shak S., Hortobagyi G.N., Livingston R.B., Yeh I.T., Ravdin P., Bugarini R., Baehner F.L., Davidson N.E., Sledge G.W., Winer E.P., Hudis C., Ingle J.N., Perez E.A., Pritchard K.I., Shepherd L., Gralow J.R., Yoshizawa C., Allred D.C., Osborne C.K., Hayes D.F. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010, 11:55-65.
2. Allard J., Hayes D.F., Repollet M., Rao C., Herman M.L., Matera J., Miller M.C., Terstappen L.W. A cellular preservative improves the specificity and yield of circulating tumor cells in carcinoma patients. Proc. Am. Soc. Clin. Oncol. 2003, 22:866.
3. Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., Tibbe A.G., Uhr J.W., Terstappen L.W. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004, 10:6897-6904.
4. Attard G., Crespo M., Lim A.C., Pope L., Zivi A., de Bono J.S. Reporting the capture efficiency of a filter-based microdevice: a CTC is not a CTC unless it is CD45 negative-letter. Clin. Cancer Res. 2011, 17:3048-3049. Author reply 3050.
5. Attard G., Swennenhuis J.F., Olmos D., Reid A.H., Vickers E., A'Hern R., Levink R., Coumans F., Moreira J., Riisnaes R., Oommen N.B., Hawche G., Jameson C., Thompson E., Sipkema R., Carden C.P., Parker C., Dearnaley D., Kaye S.B., Cooper C.S., Molina A., Cox M.E., Terstappen L.W., de Bono J.S. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009, 69:2912-2918.
6. Ausch C., Buxhofer-Ausch V., Olszewski U., Schiessel R., Ogris E., Hinterberger W., Hamilton G. Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients. J. Gastrointest. Surg. 2009, 13:2020-2026.
7. Behbakht K., Sill M.W., Darcy K.M., Rubin S.C., Mannel R.S., Waggoner S., Schilder R.J., Cai K.Q., Godwin A.K., Alpaugh R.K. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a gynecologic oncology group study. Gynecol. Oncol. 2011, 123:19-26.
8. Budd G.T., Cristofanilli M., Ellis M.J., Stopeck A., Borden E., Miller M.C., Matera J., Repollet M., Doyle G.V., Terstappen L.W., Hayes D.F. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 2006, 12:6403-6409.
9. Callagy G.M., Webber M.J., Pharoah P.D., Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008, 8:153.
10. Carr N.J. M30 expression demonstrates apoptotic cells, correlates with in situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. Arch. Pathol. Lab. Med. 2000, 124:1768-1772.
11. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M., Mitchell E., Miller M.C., Doyle G.V., Tissing H., Terstappen L.W., Meropol N.J. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:3213-3221.
12. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M.A., Mitchell E., Miller M.C., Doyle G.V., Tissing H., Terstappen L.W., Meropol N.J. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 2009, 20:1223-1229.
13. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2:647-656.
14. Coumans F.A., Doggen C.J., Attard G., de Bono J.S., Terstappen L.W. All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer. Ann. Oncol. 2010, 21:1851-1857.
15. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W., Hayes D.F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351:781-791.
16. Cristofanilli M., Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., Doyle G.V., Matera J., Allard W.J., Miller M.C., Fritsche H.A., Hortobagyi G.N., Terstappen L.W. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 2005, 23:1420-1430.
17. Cummings J., Hodgkinson C., Odedra R., Sini P., Heaton S.P., Mundt K.E., Ward T.H., Wilkinson R.W., Growcott J., Hughes A., Dive C. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol. Cancer Ther. 2008, 7:455-463.
18. de Bono J.S., Attard G., Adjei A., Pollak M.N., Fong P.C., Haluska P., Roberts L., Melvin C., Repollet M., Chianese D., Connely M., Terstappen L.W., Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin. Cancer Res. 2007, 13:3611-3616.
19. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., Doyle G.V., Terstappen L.W., Pienta K.J., Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008, 14:6302-6309.
20. Dean E.J., Cummings J., Roulston A., Berger M., Ranson M., Blackhall F., Dive C. Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia 2011, 13:339-347.
21. Dowsett M., Cuzick J., Wale C., Forbes J., Mallon E.A., Salter J., Quinn E., Dunbier A., Baum M., Buzdar A., Howell A., Bugarini R., Baehner F.L., Shak S. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 2010, 28:1829-1834.
22. Fehm T., Becker S., Becker-Pergola G., Sotlar K., Gebauer G., Durr-Storzer S., Neubauer H., Wallwiener D., Solomayer E.F. Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res. 2006, 8:R60.
23. Fehm T., Muller V., Aktas B., Janni W., Schneeweiss A., Stickeler E., Lattrich C., Lohberg C.R., Solomayer E., Rack B., Riethdorf S., Klein C., Schindlbeck C., Brocker K., Kasimir-Bauer S., Wallwiener D., Pantel K. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res. Treat. 2010, 124:403-412.
24. Fehm T., Muller V., Alix-Panabieres C., Pantel K. Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res. 2008, 10(Suppl. 1):S1.
25. Hagg M., Biven K., Ueno T., Rydlander L., Bjorklund P., Wiman K.G., Shoshan M., Linder S. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest. New Drugs 2002, 20:253-259.
26. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., Somerfield M.R., Hayes D.F., Bast R.C. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25:5287-5312.
27. Hayes D.F., Bast R.C., Desch C.E., Fritsche H., Kemeny N.E., Jessup J.M., Locker G.Y., Macdonald J.S., Mennel R.G., Norton L., Ravdin P., Taube S., Winn R.J. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 1996, 88:1456-1466.
28. Hayes D.F., Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Miller M.C., Matera J., Allard W.J., Doyle G.V., Terstappen L.W. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 2006, 12:4218-4224.
29. Hayes D.F., Smerage J. Is there a role for circulating tumor cells in the management of breast cancer?. Clin. Cancer Res. 2008, 14:3646-3650.
30. Hayes D.F., Walker T.M., Singh B., Vitetta E.S., Uhr J.W., Gross S., Rao C., Doyle G.V., Terstappen L.W. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int. J. Oncol. 2002, 21:1111-1117.
31. Hou J.M., Greystoke A., Lancashire L., Cummings J., Ward T., Board R., Amir E., Hughes S., Krebs M., Hughes A., Ranson M., Lorigan P., Dive C., Blackhall F.H. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am. J. Pathol. 2009, 175:808-816.
32. Ignatiadis M., Xenidis N., Perraki M., Apostolaki S., Politaki E., Kafousi M., Stathopoulos E.N., Stathopoulou A., Lianidou E., Chlouverakis G., Sotiriou C., Georgoulias V., Mavroudis D. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J. Clin. Oncol. 2007, 25:5194-5202.
33. Kallergi G., Mavroudis D., Georgoulias V., Stournaras C. Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol. Med. 2007, 13:79-88.
34. Koelink P.J., Lamers C.B., Hommes D.W., Verspaget H.W. Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 2009, 9:88.
35. Kraan J., Sleijfer S., Strijbos M.H., Ignatiadis M., Peeters D., Pierga J.Y., Farace F., Riethdorf S., Fehm T., Zorzino L., Tibbe A.G., Maestro M., Gisbert-Criado R., Denton G., de Bono J.S., Dive C., Foekens J.A., Gratama J.W. External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study. Cytometry B Clin. Cytom. 2011, 80:112-118.
36. Leers M.P., Kolgen W., Bjorklund V., Bergman T., Tribbick G., Persson B., Bjorklund P., Ramaekers F.C., Bjorklund B., Nap M., Jornvall H., Schutte B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 1999, 187:567-572.
37. Ligthart S.T., Coumans F.A., Attard G., Cassidy A.M., de Bono J.S., Terstappen L.W. Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One 2011, 6:e27419.
38. Lipponen P., Aaltomaa S., Kosma V.M., Syrjanen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur. J. Cancer 1994, 30A:2068-2073.
39. Liu M.C., Shields P.G., Warren R.D., Cohen P., Wilkinson M., Ottaviano Y.L., Rao S.B., Eng-Wong J., Seillier-Moiseiwitsch F., Noone A.M., Isaacs C. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J. Clin. Oncol. 2009, 27:5153-5159.
40. Liu S., Edgerton S.M., Moore D.H., Thor A.D. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin. Cancer Res. 2001, 7:1716-1723.
41. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., Inserra E., Diederichs S., Iafrate A.J., Bell D.W., Digumarthy S., Muzikansky A., Irimia D., Settleman J., Tompkins R.G., Lynch T.J., Toner M., Haber D.A. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 2008, 359:366-377.
42. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst. 2005, 97:1180-1184.
43. Meng S., Tripathy D., Frenkel E.P., Shete S., Naftalis E.Z., Huth J.F., Beitsch P.D., Leitch M., Hoover S., Euhus D., Haley B., Morrison L., Fleming T.P., Herlyn D., Terstappen L.W., Fehm T., Tucker T.F., Lane N., Wang J., Uhr J.W. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 2004, 10:8152-8162.
44. Meng S., Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., Beitsch P., Khan A., Euhus D., Osborne C., Frenkel E., Hoover S., Leitch M., Clifford E., Vitetta E., Morrison L., Herlyn D., Terstappen L.W., Fleming T., Fehm T., Tucker T., Lane N., Wang J., Uhr J. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. U S A 2004, 101:9393-9398.
45. Meng S., Tripathy D., Shete S., Ashfaq R., Saboorian H., Haley B., Frenkel E., Euhus D., Leitch M., Osborne C., Clifford E., Perkins S., Beitsch P., Khan A., Morrison L., Herlyn D., Terstappen L.W., Lane N., Wang J., Uhr J. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc. Natl. Acad. Sci. U S A 2006, 103:17361-17365.
46. Nagrath S., Sequist L.V., Maheswaran S., Bell D.W., Irimia D., Ulkus L., Smith M.R., Kwak E.L., Digumarthy S., Muzikansky A., Ryan P., Balis U.J., Tompkins R.G., Haber D.A., Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239.
47. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., Wolmark N. A multi-gene RT-PCR assay using fixed, paraffin-embedded tumor tissue to predict the likelihood of breast cancer recurrence in node negative, estrogen receptor positive, tamoxifen-treated patients. N. Engl. J. Med. 2004, 351:2817-2826.
48. Riethdorf S., Muller V., Zhang L., Rau T., Loibl S., Komor M., Roller M., Huober J., Fehm T., Schrader I., Hilfrich J., Holms F., Tesch H., Eidtmann H., Untch M., von Minckwitz G., Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 2010, 16:2634-2645.
49. Rossi E., Basso U., Celadin R., Zilio F., Pucciarelli S., Aieta M., Barile C., Sava T., Bonciarelli G., Tumolo S., Ghiotto C., Magro C., Jirillo A., Indraccolo S., Amadori A., Zamarchi R. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin. Cancer Res. 2010, 16:5233-5243.
50. Rossi E., Fassan M., Aieta M., Zilio F., Celadin R., Borin M., Grassi A., Troiani L., Basso U., Barile C., Sava T., Lanza C., Miatello L., Jirillo A., Rugge M., Indraccolo S., Cristofanilli M., Amadori A., Zamarchi R. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br. J. Cancer 2012, 107:1286-1294.
51. Russo A., Terrasi M., Agnese V., Santini D., Bazan V. Apoptosis: a relevant tool for anticancer therapy. Ann. Oncol. 2006, 17(Suppl 7):vii115-vii123.
52. Simon R.M., Paik S., Hayes D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 2009, 101:1446-1452.
53. Teutsch S.M., Bradley L.A., Palomaki G.E., Haddow J.E., Piper M., Calonge N., Dotson W.D., Douglas M.P., Berg A.O. The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP working group. Genet. Med. 2009, 11:3-14.
54. Vakkala M., Lahteenmaki K., Raunio H., Paakko P., Soini Y. Apoptosis during breast carcinoma progression. Clin. Cancer Res. 1999, 5:319-324.
55. Zheng S., Lin H., Liu J.Q., Balic M., Datar R., Cote R.J., Tai Y.C. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J. Chromatogr. A 2007, 1162:154-161.